Australia’s multi-award winning AtomoRapid; HIV blood test designed to reduce test errors at home

Australia’s multi-award winning AtomoRapid; HIV blood test designed to reduce test errors at home

Sydney, Australia | Atomo Diagnostics today congratulated the Australian Government on its move to lift restrictions on home HIV tests in a bid to end new HIV infections by 2020.

Atomo Diagnostics says it wants to play a significant role in supporting this Government initiative with its proven and multi-award winning AtomoRapid™ HIV rapid blood test.

Former ResMed executive and Atomo Diagnostics’ founder and CEO John Kelly said, we have seen from our work with the Desmond Tutu HIV Foundation in South Africa that if you want to be accepted as an at-home test you need an integrated intuitive solution that reduces test errors.

AtomoRapid™ HIV took the top international medical technology award last month in New York at the Medical Design Excellence Awards, with its all-in-one HIV test, which is the half the size of an iPhone.

” AtomoRapid™ HIV is fast, low cost, accurate, and fundamentally changes the use and business model in this important space. It’s the Early Pregnancy Test (EPT) for HIV,” said one of the medical industry leader judges, George L. Walls, at the awards.

“We can now officially say we are best in the world,” said the Australian AtomoRapid™ team after the awards.

The handheld disposable AtomoRapid™ HIV device is currently being distributed in Southern Africa where accuracy and in the field testing have long challenged the management of HIV.

“To ensure superior performance, the AtomoRapid™ HIV product uses a proven HIV test strip that has been World Health Organisation (WHO) evaluated and proven,” said Kelly.

“Over 100 million rapid HIV tests are bought each year globally, and Atomo Diagnostics is leading the all-in-one innovation with AtomoRapid™,” says Kelly.

“We concentrated on HIV and malaria because that was where false negatives and false positives from other ‘bits in a box’ products, which were sometimes greater than 10 per cent when used in the field, were having the most significant impact on individuals.

Kelly was inspired to find a better way to test blood when his daughter developed a childhood disease requiring regular blood draws for diagnostic tests.

The AtomoRapid™platform can accommodate test strips for a wide variety of conditions from celiac disease and allergy through to infectious diseases such as malaria and HIV.

The device delivers better clinical outcomes for patients and health care providers by enabling simpler, safer and more accurate testing in the field or at home.

Given its ease of use and simplicity, AtomoRapid™ HIV has the ability to materially improve both the uptake and reliability of HIV testing in the community and at home. The company plans to launch the product in Australia, the US and Europe for both professional and at home use.

“Existing tests fail to offer the AtomoRapid™ all in one solution which can leave them open to errors which in turn creates misdiagnosis. For a disease such as HIV, this can have a significant impact not only on the individual, but the community too,” said John Kelly.

About Atomo Diagnostics www.atomodiagnostics.com

Atomo Diagnostics is an award-winning Australian based healthcare company that develops and commercialises next generation solutions addressing unmet user needs in the diagnostic industry.

AtomoRapid™ Malaria, the second test to market, will be available in the 3rd Quarter of 2014 and we plan to introduce additional tests in the coming 18 months.

The company is actively seeking partners for market entry into the US and Europe.

 

About the Medical Design Excellence Award (MDEA) win last month

The Medical Design Excellence Awards are judged by an impartial med tech experts. Unlike other design competitions, the MDEA jury is comprised of a balance of practicing doctors, nurses, and technicians alongside industrial designers, engineers, manufacturers, and human factors experts. MDEA jurors comprehensively review entries based on the following criteria: the ability of the product development team to overcome all challenges so the product meets its clinical objectives; innovative use of materials, components, and processes; user-related functions improving healthcare delivery and changing traditional medical attitudes or practices; features providing enhanced benefits to the patient and end-user in relation to clinical efficacy; manufacturing cost-effectiveness and profitability; and healthcare system benefits such as improved accessibility, efficacy, or safety, in addition to providing attention to a critical unmet clinical need.